Personalizing medicine for metastatic colorectal cancer: current developments

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic colorectal cancer (mCRC) presents significant global health challenges, with high incidence and mortality rates.
• Early diagnosis is crucial, yet approximately 25% of patients present with metastases, leading to poor prognoses.
• Limited survival rates underscore the urgent need for innovative therapeutic approaches.

Purpose of the Study:

• To review key molecular pathways implicated in tumor growth in mCRC.
• To summarize novel targeted therapies and recently approved drugs for mCRC treatment.
• To highlight the role of molecular biology in developing personalized medicine for mCRC.

Main Methods:

• Literature review of molecular pathways in mCRC.
• Analysis of targeted therapies focusing on angiogenesis, EGFR, and KRAS pathways.
• Summary of recent drug approvals and ongoing research in mCRC treatment.

Main Results:

• Targeted therapies, including those modulating angiogenesis, epidermal growth factor receptor (EGFR), and KRAS pathways, show promise.
• Understanding genetic mutations and polymorphisms explains differential treatment responses.
• Personalized treatment strategies are becoming increasingly feasible.

Conclusions:

• Targeted therapies, combined with standard treatments, are revolutionizing mCRC management.
• Advances in molecular biology enable tailored treatments based on individual patient profiles.
• Continued research into molecular pathways and targeted drugs is essential for improving mCRC outcomes.